Latest Content

Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.

Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.

Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.

In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.

Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.

Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.

OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.

Micvotabart pelidotin produced a 36% confirmed ORR and a 6.2-month median PFS in pretreated recurrent/metastatic head and neck squamous cell carcinoma.

The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.

Dabogratinib led to a high rate of responses FGFR3-altered low-grade intermediate-risk non–muscle-invasive bladder cancer.

Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.

A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings

Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.

Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.

D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.

Arlocabtagene autoleucel met the primary end point of overall response rate in the registrational phase 2 QUINTESSENTIAL trial.

Patients with triple-class–exposed relapsed/refractory multiple myeloma reported improvements in pain, fatigue, and functioning during up to 2 years of linvoseltamab.

Pegylated G-CSF produced rates of successful CD34-positive cell collection and safety comparable to daily G-CSF in healthy allogeneic transplant donors.

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.

The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.

Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.

The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.

Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.

Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.

Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.

Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.

Alcohol-attributable cancer deaths in the U.S. doubled from about 11,400 in 1990 to more than 23,100 in 2023.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.

GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.

Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.

A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.

A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at Dana-Farber Cancer Institute.

JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.

MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.